2QG Stock Overview
A biopharmaceutical company, engages in the development of drugs to treat cardiovascular diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Quantum Genomics Société Anonyme Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.088 |
| 52 Week High | €0.17 |
| 52 Week Low | €0.077 |
| Beta | 0.71 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -98.16% |
| 5 Year Change | -98.22% |
| Change since IPO | -95.15% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2QG | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.2% | 0.8% |
| 1Y | n/a | -16.9% | 9.1% |
Return vs Industry: Insufficient data to determine how 2QG performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 2QG performed against the German Market.
Price Volatility
| 2QG volatility | |
|---|---|
| 2QG Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2QG has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 2QG's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 4 | Jean-Philippe Milon | www.quantum-genomics.com |
Quantum Genomics Société Anonyme, a biopharmaceutical company, engages in the development of drugs to treat cardiovascular diseases. The company develops its drugs based on brain inhibition mechanism of Aminopeptidase A: BAPAI, a triple-action therapeutic platform primarily to treat high blood pressure and heart failure. It is developing firibastat, a treatment for high blood pressure, and in combination with others anti-hypertensive drugs.
Quantum Genomics Société Anonyme Fundamentals Summary
| 2QG fundamental statistics | |
|---|---|
| Market cap | €3.56m |
| Earnings (TTM) | -€18.07m |
| Revenue (TTM) | €19.92k |
178.5x
P/S Ratio-0.2x
P/E RatioIs 2QG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2QG income statement (TTM) | |
|---|---|
| Revenue | €19.92k |
| Cost of Revenue | €19.75m |
| Gross Profit | -€19.73m |
| Other Expenses | -€1.65m |
| Earnings | -€18.07m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.52 |
| Gross Margin | -99,061.89% |
| Net Profit Margin | -90,752.20% |
| Debt/Equity Ratio | 179.2% |
How did 2QG perform over the long term?
See historical performance and comparison